Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07112690 · ClinicalTrials.gov registry record · NA
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
A NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT07112690: Recruiting NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma, sponsored by Emory University.
NCT07112690 is a NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07112690, a NA study of Stage I Anal Cancer AJCC v8 and Localized Anal Carcinoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized). Treatment for anal or perianal skin cancer includes giving chemotherapy and radiation therapy (CRT) at the same time. CRT is frequently associated with several side effects, including radiation-induced pain. Despite advances in radiation therapy delivery, patients may still experience side effects which can lead to treatment breaks or treatment discontinuation. Ganglion impar neurolysis is a type of nerve block procedure in which medicine is injected directly into or around a nerve to block pain. The location of the procedure is near the tail bone and the medicine numbs the nerves that are in charge of sensation in the skin by the buttocks and genitalia. This may improve radiation-induced pain in patients receiving CRT for localized anal or perianal skin cancer.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Electronic Health Record Review
- PROCEDURE Fluoroscopy
- PROCEDURE Ganglion Impar Neurolysis
Study Locations (2)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Grady Health System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
What NCT07112690 shows while recruiting
NCT07112690 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 6 conditions, with Stage I Anal Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT07112690 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07112690 about?
NCT07112690 is a clinical study titled "Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment". This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized). Treatment for anal or perianal skin cancer includes giving chemotherapy and radiatio...
What is the current status of trial NCT07112690?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2025-11-10. Estimated completion is 2027-09-30.
What conditions does trial NCT07112690 study?
This clinical trial studies the following conditions: Stage I Anal Cancer AJCC v8, Localized Anal Carcinoma, Localized Anal Margin Carcinoma, Stage 0 Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8.
What interventions are being tested in trial NCT07112690?
The interventions under investigation include: Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER), Fluoroscopy (PROCEDURE), Ganglion Impar Neurolysis (PROCEDURE).
Who is sponsoring clinical trial NCT07112690?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07112690 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage I Anal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07112690's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI